WEBVTT

1
00:00:01.000 --> 00:00:04.660
Mazdutide closes this group with a different milestone,

2
00:00:05.620 --> 00:00:10.560
a dual GLP-1 and glucagon receptor medicine that

3
00:00:10.560 --> 00:00:12.320
reached approval in China.

4
00:00:13.300 --> 00:00:17.220
It originated in Lilly's research, Innovent licensed development

5
00:00:17.220 --> 00:00:20.360
and commercial rights in China in 2019,

6
00:00:21.220 --> 00:00:24.940
connecting American discovery with Chinese clinical development.

7
00:00:25.760 --> 00:00:30.160
Linong Ji and colleagues tested it in GLORY-1.

8
00:00:30.780 --> 00:00:35.540
610 adults in China, randomized to Mazdutide or

9
00:00:35.540 --> 00:00:38.020
placebo for 48 weeks.

10
00:00:38.720 --> 00:00:42.180
Average weight fell 11% in the 4 mg group

11
00:00:42.180 --> 00:00:47.540
and 14.01% in the 6 milligram group.

12
00:00:48.020 --> 00:00:52.000
Placebo participants gained 0.3%.

13
00:00:52.000 --> 00:00:55.420
This analysis includes people who stopped treatment or

14
00:00:55.420 --> 00:00:57.100
started other weight therapies.

15
00:00:57.790 --> 00:01:01.670
Gastrointestinal symptoms were the most common adverse events.

16
00:01:02.730 --> 00:01:06.750
Population averages cannot predict every individual response.

17
00:01:07.710 --> 00:01:10.890
China approved Mazdutide for weight management and type

18
00:01:10.890 --> 00:01:13.430
2 diabetes in 2025.

19
00:01:14.140 --> 00:01:15.760
These are separate indications.

20
00:01:16.460 --> 00:01:20.060
The obesity trial does not establish diabetes outcomes

21
00:01:20.060 --> 00:01:23.460
and approval in one country does not authorize

22
00:01:23.460 --> 00:01:24.700
use everywhere.

23
00:01:25.800 --> 00:01:28.500
As this group ends, connect each claim to

24
00:01:28.500 --> 00:01:30.380
its population, measurement,

25
00:01:31.160 --> 00:01:33.260
safety record and local approval.

26
00:01:34.140 --> 00:01:37.660
The evidence continues beyond any single film.

27
00:01:37.660 --> 00:01:40.080
Peptides in 2.

28
00:01:40.080 --> 00:01:41.960
World Peptide Foundation.

29
00:01:42.860 --> 00:01:43.960
Every experience matters.